Quantcast

Latest MiMedx Group Inc. Stories

2014-05-12 08:32:21

MARIETTA, Ga., May 12, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its Board of Directors has approved a stock repurchase program. Under the terms of the program, the Company may repurchase up to $10 million of its common stock from time to time through December 31, 2014. The timing and amount of...

2014-05-06 16:33:25

MARIETTA, Ga., May 6, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that two of its peer-reviewed scientific studies have been published in the scientific literature. The Company's study "Angiogenic Properties of Dehydrated Human Amnion/Chorion Allografts: Therapeutic Potential for Soft Tissue Repair and...

2014-04-29 16:32:03

Company Amends its Patent Infringement Lawsuit to Include Two Additional Patents MARIETTA, Ga., April 29, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of four newly issued patents related to the Company's tissue allografts derived from the placenta. On April 22, 2014, the U.S. Patent and...

2014-04-28 12:30:43

EDISON, N.J., April 28, 2014 /PRNewswire/ -- The Musculoskeletal Transplant Foundation (MTF) has been notified that on April 21, 2014, MiMedx Group, Inc. (MiMedx) filed a complaint in the United States District Court for the Northern District of Georgia, naming MTF, together with Liventa Bioscience, Inc. and Medline Industries Inc., as defendants. The complaint alleges patent infringement by MTF of four MiMedx patents. MTF does not believe it infringes any of the patents and is...

2014-04-23 12:29:55

EpiFix® is shown to promote rapid healing and return to function for patients and provide a potential for significant cost savings. MARIETTA, Ga., April 23, 2014 /PRNewswire/ -- EpiFix®, dehydrated human amnion/chorion membrane (dHACM) allografts, were shown to be clinically and cost effective in the treatment of multiple hard-to-treat wounds like diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers (PUs), according to data and case experiences being presented at the...

2014-04-22 08:33:34

MARIETTA, Ga., April 22, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has filed a patent infringement lawsuit against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified...

2014-04-21 08:25:20

MARIETTA, Ga., April 21, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its sponsorship of Scott Rigsby, a double-amputee athlete. As part of the relationship, Rigsby will be taking his "inspire, inform, enable" message to Boston as he returns to run the 2014 Boston Marathon on April 21. Rigsby was 18 when...

2014-04-07 08:31:10

COMPANY ANNOUNCES SECOND QUARTER REVENUE GUIDANCE MARIETTA, Ga., April 7, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its first quarter of 2014 revenue slightly exceeded the upper end of its previously announced guidance. The Company also announced its guidance for the second quarter of 2014....

2014-04-02 16:31:06

MARIETTA, Ga., April 2, 2014 /PRNewswire/ -- MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the first quarter ended March 31, 2014, will be released before the opening of the market on Friday, April 25, 2014. MiMedx will host a live broadcast of its first quarter conference call on Friday, April 25, 2014 at 10:30am EDT....

2014-03-24 08:29:27

COMPANY ALSO RAISES LOWER END OF 2014 REVENUE GUIDANCE MARIETTA, Ga., March 24, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it will host a shareholder call tomorrow, Tuesday, March 25, 2014 at 11:00 AM Eastern Time to update shareholders on the positive progress of its discussions with the Food and...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related